Portal de Periódicos da CAPES

The Suicide Gene Therapy Challenge: How to Improve a Successful Gene Therapy Approach

2007; Elsevier BV; Volume: 15; Issue: 7 Linguagem: Inglês

10.1038/sj.mt.6300190

1525-0024

Chiara Bonini, Attilio Bondanza, Serena K. Perna, Shin Kaneko, Catia Traversari, Fabio Ciceri, Claudio Bordignon,

CRISPR and Genetic Engineering

The transfer of a suicide gene into donor lymphocytes to control alloreactivity in the context of allogeneic hematopoietic stem cell transplantation (allo-HSCT) represents the widest clinical application of T-cell based gene transfer, as shown by more than 100 patients treated worldwide to date, several phase I–II studies completed, and a registrative phase III study, sponsored by a biotech firm, about to begin. In this mini-review, we will summarize the clinical results obtained to date, and attempt to identify the steps envisaged to optimize the suicide gene therapy approach. The transfer of a suicide gene into donor lymphocytes to control alloreactivity in the context of allogeneic hematopoietic stem cell transplantation (allo-HSCT) represents the widest clinical application of T-cell based gene transfer, as shown by more than 100 patients treated worldwide to date, several phase I–II studies completed, and a registrative phase III study, sponsored by a biotech firm, about to begin. In this mini-review, we will summarize the clinical results obtained to date, and attempt to identify the steps envisaged to optimize the suicide gene therapy approach.